APA (7th ed.) Citation

MC, C., CFD, L. W. S., D, C., K, B., R, P., K, B., . . . P, D. C. (2024). Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): An open-label, multicentre, randomised controlled trial. The lancet. Gastroenterology & hepatology, 9(11), 981. https://doi.org/10.1016/S2468-1253(24)00200-0

Chicago Style (17th ed.) Citation

MC, Choy, et al. "Intensified Versus Standard Dose Infliximab Induction Therapy for Steroid-refractory Acute Severe Ulcerative Colitis (PREDICT-UC): An Open-label, Multicentre, Randomised Controlled Trial." The Lancet. Gastroenterology & Hepatology 9, no. 11 (2024): 981. https://doi.org/10.1016/S2468-1253(24)00200-0.

MLA (9th ed.) Citation

MC, Choy, et al. "Intensified Versus Standard Dose Infliximab Induction Therapy for Steroid-refractory Acute Severe Ulcerative Colitis (PREDICT-UC): An Open-label, Multicentre, Randomised Controlled Trial." The Lancet. Gastroenterology & Hepatology, vol. 9, no. 11, 2024, p. 981, https://doi.org/10.1016/S2468-1253(24)00200-0.